Agios' high metabolism

Massachusetts Institute of Technology, Agios Pharmaceuticals Inc. and other collaborators have used an RNAi-based in vivo screening technology to discover cancer targets directly related to tumor metabolism. The team applied the approach to a subset of metabolic genes and identified phosphoglycerate dehydrogenase, a key enzyme in serine biosynthesis, as being involved in breast cancer.¹

The same team is now screening the complete set of human metabolic genes to identify additional cancer targets...